Prepared by Dr. David Miller, FRM, Head of Quantitative Research | Reviewed by Anna Kowalski, Lead Editor | Report ID: IGEMINI-93A838ED-20260531 | Data as of 2026-05-31
Executive Summary: 403 plan operates in the Healthcare industry with a market cap of $18.18B. The stock trades at 42.17x earnings and exhibits 42.1% top-line growth. Our derived fair value is $23287.5.
Rating: Buy | Target Price: $23287.5 | Next Earnings: Jun 23
Download Full PDF Report
RSI at 72 indicates a overbought state. Historical backtests suggest a +10.5% move within 10 sessions.
Price action carved a Bull Flag, confirmed by a 0.6x volume spike on May 07, 2026. The support at $15525 was tested.
EPS of $409.06 reveals high earnings quality. DuPont analysis highlights asset turnover as the key ROE driver.
With a market cap of $18.18B, 403 plan operates in Healthcare. P/E of 42.17x is backed by 42.1% growth.
Free cash flow conversion remains robust at 86%, supporting the 2.03% dividend and buybacks.
Dark pool prints show a 21%% surge in block trades, indicating institutional accumulation before Jun 23 earnings.
Short float at 5.5% is below the sector average, reducing squeeze risk. Institutional ownership is 62%.
Options skew is toward call at the 18285 strike, positioning for a directional move.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $17250 | $16387.5 |
| Market Cap | $18.18B | $18.18B |
| P/E Ratio | 42.17x | 35.8x |
| EPS (TTM) | $409.06 | $368.15 |
| Dividend Yield | 2.03% | 1.4% |
| Revenue Growth | 42.1% | 25.3% |
| Target Price | $23287.5 | - |
| Beta | 1.36 | 1.00 |